Dear Shareholder:
On January 3rd, I wrote a letter updating you, our shareholders,
on the status of events that I thought would affect each of you in
a positive way. Please see the link if you missed this.
https://ir.alliqua.com/press-releases/detail/794/alliqua-biomedical-ceo-provides-update-to-shareholders.
Today, I would like to provide a further update to that
letter.
First, as you have probably seen, we declared a special dividend
of $1.05 per share with a record date of April 22nd, 2019.
However, we think the real excitement is now about two deals
we have in progress with companies that our Alliqua shareholders
will own shares in upon the closing of these transactions.
Let me start with Adynxx.
Great progress has been made with this exciting company,
including receipt of a substantial grant award from the National
Institute on Drug Abuse to support the clinical development of
brivoligide, the company’s lead product intended to both reduce
postoperative pain and the need for opioid-based therapies. I will
let the company provide a more thorough update on their
progress.
http://www.adynxx.com/news/adynxx-announces-merger-agreement-with-alliqua-biomedical-and-provides-business-and-clinical-update
Now, let’s speak about TO Pharma.
TO Pharma (TOP) offers you two ways to win. First, TOP intends
to use the 20,000 patient records they developed over the past 10
years with Tikun Olam Israel, to identify the most appropriate
assets to take through an FDA process with a proprietary
extract, Avidekel. Second, TOP intends to leverage our
16,000 square foot hydrogel manufacturing facility in
Langhorne, PA to build a portfolio of Consumer Products. We
are excited about the creation of this new public
bio-pharmaceutical company focused on discovering, developing and
commercializing novel therapeutics based on TOP’s proprietary
cannabinoid product platform in a number of FDA-regulated clinical
indications and in select OTC markets.
So yes, we continue to make progress and we are confident this
progress should create additional shareholder value. As a
shareholder of Alliqua Biomedical, you will own shares in both of
these exciting companies. Thus, you really have three ways to win
with your Alliqua shares:
1). A cash dividend of $1.05
2). Shares in Adynxx, an exciting company developing novel,
disease-modifying therapies for pain and inflammatory diseases with
a lead product candidate in Phase for reducing pain and opioid use
after surgery.
3). Shares in TO Pharma, an exciting company looking to leverage
cannabinoid for multiple indications and planned product
offerings.
We thank you for being a shareholder of Alliqua.
Dave
David I JohnsonCEOAlliqua Biomedical
About Alliqua BioMedical, Inc.Alliqua, through its AquaMed
subsidiary, can provide a custom manufacturing solution to partners
in the medical device; cosmetics; and OTC industry, utilizing its
proprietary hydrogel technology. Alliqua's electron beam production
process, located at its 16,500 square foot GMP manufacturing
facility in Langhorne, PA, allows Alliqua to custom manufacture a
wide variety of hydrogels. Alliqua's hydrogels can be customized
for various transdermal applications to address market
opportunities in the treatment of wounds as well as the delivery of
numerous drugs or other agents for pharmaceutical and cosmetic
industries.
About Adynxx, Inc.Adynxx is a clinical stage biopharmaceutical
company focused on bringing to market novel, disease-modifying
products for the treatment of pain and inflammation. Adynxx’s
pipeline includes brivoligide, a Phase 2 drug candidate intended to
address postoperative pain in a readily-identified group of
patients with a greater risk of experiencing increased pain and
elevated opioid use following surgery, and AYX2, a pre-clinical
candidate intended to treat chronic syndromes of pain, including
both inflammatory and neuropathic pain. Both programs were
discovered by Adynxx and are part of the AYX transcription factor
decoy technology platform, and brivoligide development is supported
with a $5.7M grant award from the National Institute on Drug
Abuse.
About TO PharmaceuticalsTO Pharmaceuticals LLC is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics based on its proprietary
cannabinoid product platform in a number of FDA-regulated clinical
indications and in select OTC markets. TOP is exclusively licensed
worldwide to utilize the pharmaceutical intellectual property
developed by Tikun Olam Limited.
About Tikun Olam LimitedTikun Olam ("repair the world" in
Hebrew) is globally recognized as the pioneer of modern medical
cannabis. Since 2010, its products have been the subject of ongoing
clinical trials and have been relied upon to treat over 20,000
patients in Israel’s regulated market for symptoms of conditions
including cancer, PTSD, AIDS, epilepsy, Crohn's Disease/colitis,
multiple sclerosis, cerebral palsy, chronic pain and neuropathy.
The growing international network of Tikun Olam affiliates
includes, among others, the USA’s T.O. Global, LLC, Canada’s
MedReleaf and Australia’s Medifarm.
Forward Looking Statements Statements in this press release that
are not a description of historical fact are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
the use of words referencing future events or circumstances such as
“expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,”
among others. Such statements include, but are not limited to,
statements regarding the cash dividend and the structure, timing
and completion of the proposed transactions with Adynxx, Inc. and
TOP, and statements regarding the expected benefits to be realized
as a result of these transactions. These statements represent
Alliqua’s intentions, plans, expectations and beliefs, and no
assurance can be given that the results described in such
statements will be achieved. Alliqua, Adynxx, Inc. and/or TOP
may not actually consummate the proposed transactions or any plans
or product development goals, in a timely manner, if at all, or
otherwise carry out the intentions or meet the expectations or
projections disclosed in our forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon Alliqua's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Risks and uncertainties facing Alliqua
are described more fully in Alliqua's periodic reports filed with
the SEC available at www.sec.gov. You are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date on which they were made. Alliqua undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made,
except as may be required by law.
Alliqua BioMedical, Inc. ir@alliqua.com
Source: Alliqua BioMedical, Inc
Alliqua, Inc. (NASDAQ:ALQA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alliqua, Inc. (NASDAQ:ALQA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024